Abbvie Inc. Common Stock (ABBV) 59.98 $ABBV
Will AbbVie (ABBV) Disappoint in this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 2:28PM CDT
AbbVie (ABBV) is scheduled to report its third-quarter 2014 results before the opening bell on Oct 31.
INCY: 57.87 (-0.32), TEVA: 54.49 (-0.31), AMAG: 33.26 (-0.75), ABBV: 59.98 (-0.95)
3 Health Care Picks To Beat Earnings - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 11:09AM CDT
These stocks are well positioned in today's market environment.
ENDP: 65.65 (-0.93), VRX: 129.76 (-1.31), ACT: 238.78 (-0.25), AMGN: 158.88 (+1.69), TKMR: 16.87 (-1.46), GSK: 45.08 (-0.02), AGN: 186.77 (+4.17), JNJ: 105.56 (+0.77), SHPG: 196.45 (-1.35), MRK: 56.20 (+0.35), INFI: 13.58 (-0.08), ABBV: 59.98 (-0.95), KPTI: 39.81 (+1.78)
Gilead Beats on Q3 Earnings, Sovaldi Sales Fall Sequentially - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 8:00AM CDT
Gilead Sciences, Inc. reported third-quarter earnings (including stock-based compensation expenses) of $1.79 per share.
AGN: 186.77 (+4.17), GILD: 110.72 (-2.73), MRK: 56.20 (+0.35), ABBV: 59.98 (-0.95)
If You Purchased Shire plc American Depository Receipts ("ADRs"
During The Period Of June 20, 2014 And October 14, 2014 And Lost Money, Gardy & Notis, LLP Encourages You To Contact The Law Firm
PR Newswire - Wed Oct 29, 7:38AM CDT
Gardy & Notis, LLP, a national law firm advocating for shareholder rights, is investigating AbbVie Inc. (NYSE: ABBV) and its officers and directors in connection with statements distributed by, or on behalf of, AbbVie to purchasers of Shire plc ADRs (NASDAQ: SHPG) and the general investing public regarding AbbVie's rationale for pursuing a business combination with Shire.
SHPG: 196.45 (-1.35), ABBV: 59.98 (-0.95)
Compliance Notice, Dividend Announcements, New Share Repurchase Program, and Financial Results - Research Reports on Gilead, Pfizer, AbbVie, Edwards and Lilly
PR Newswire - Wed Oct 29, 7:35AM CDT
Today, Analysts Review released its research reports regarding Gilead Sciences, Inc. (NASDAQ: GILD), Pfizer Inc. (NYSE: PFE), AbbVie Inc. (NYSE: ABBV), Edwards Lifesciences Corp. (NYSE: EW) and Eli Lilly and Co. (NYSE: LLY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7520-100free.
GILD: 110.72 (-2.73), PFE: 29.49 (+0.40), EW: 120.00 (+1.72), LLY: 65.49 (+0.66), ABBV: 59.98 (-0.95)
Pfizer Q3 Earnings Top Estimates Despite Generic Pressure - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 3:10PM CDT
Pfizer's (PFE) third quarter earnings and revenues were better-than-expected despite the presence of generic pressure.
AGN: 186.77 (+4.17), BIIB: 315.06 (-2.97), PFE: 29.49 (+0.40), ABBV: 59.98 (-0.95)
Amgen Refuses To Split, But Plans Hearten Investors
at Investor's Business Daily - Tue Oct 28, 1:18PM CDT
Big-cap biotech Amgen (AMGN) offered 2015 guidance, set 2018 targets and resisted pressure to split at a business-review meeting Tuesday. On the heels of Monday's Q3 earnings beat, Amgen's action helped drive the stock up more than 5% in afternoon...
AMGN: 158.88 (+1.69), ABBV: 59.98 (-0.95)
Receptos Soars After Lead Drug Racks Up Another Win
at Investor's Business Daily - Tue Oct 28, 10:46AM CDT
Receptos (RCPT) stock jumped more than 47% to a new high above 99 in morning trading on the stock market today, and the company got multiple price-target increases after its bowel-disease drug succeeded in a midstage trial. Receptos announced late...
JNJ: 105.56 (+0.77), RCPT: 98.30 (+2.54), ABBV: 59.98 (-0.95)
3 Generics Stocks to Buy Now - Analyst Blog
Swarup Gupta - Zacks Investment Research - Tue Oct 28, 9:28AM CDT
Data from IMS health show that 29% of expenditure on prescription drugs in the U.S. can be attributed to generics.
MNK: 93.01 (-0.73), ABT: 42.74 (+0.24), ACT: 238.78 (-0.25), MYL: 50.85 (-0.86), ABBV: 59.98 (-0.95)
Was AbbVie Inc. Wrong to Abandon Its Deal With Shire plc?
Todd Campbell, The Motley Fool - Motley Fool - Tue Oct 28, 8:45AM CDT
Source: Shire Tax inversions are dead. The Treasury Department made sure of that in September, when it released a shopping list of changes to rein in proposed transactions like the one previously planned between AbbVie and Shire plc . ...
SHPG: 196.45 (-1.35), ABBV: 59.98 (-0.95)
Global Schizoaffective Disorder Clinical Trials Report H2, 2014
M2 - Tue Oct 28, 5:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3w59x2/schizoaffective) has announced the addition of the "Schizoaffective Disorder Global Clinical Trials Review, H2, 2014" report to their offering. Schizoaffective Disorder Global Clinical Trials Review, H2, 2014" provides data on the Schizoaffective Disorder clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Schizoaffective Disorder. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Schizoaffective Disorder. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies - Johnson & Johnson - Pfizer Inc. - Eli Lilly and Company - AstraZeneca PLC - Bristol-Myers Squibb Company - Sumitomo Dainippon Pharma Co., Ltd. - Otsuka Holdings Co., Ltd. - AbbVie Inc. - North Shore-Long Island Jewish Health System, Inc. - Merck & Co., Inc. Top Institutes / Government - U.S. Department of Veterans Affairs - University of Maryland - University of Pittsburgh - Yale University - Centre for Addiction and Mental Health - National Institute of Mental Health - Vanderbilt University - Dartmouth-Hitchcock Medical Center - Massachusetts General Hospital - North Suffolk Mental Health Association For more information visit http://www.researchandmarkets.com/research/3w...oaffective
JNJ: 105.56 (+0.77), PFE: 29.49 (+0.40), MRK: 56.20 (+0.35), AZN: 71.53 (+0.10), LLY: 65.49 (+0.66), ABBV: 59.98 (-0.95), BMY: 54.16 (-0.04)
Video: Allergan Lifts Views; Valeant Suggests Higher Bid
at Investor's Business Daily - Mon Oct 27, 11:17AM CDT
Specialty drugmaker Allergan (AGN) reported solid Q3 results and raised its guidance Monday, as hostile suitor Valeant Pharmaceuticals International (VRX) said that it might raise its bid for the company again. Allergan's Q3 earnings rose 45% over...
AGN: 186.77 (+4.17), ACT: 238.78 (-0.25), VRX: 129.76 (-1.31), SHPG: 196.45 (-1.35), ABBV: 59.98 (-0.95)
Stock Market News for October 27, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 9:10AM CDT
Benchmarks posted solid gains on Friday, banking on upbeat quarterly results from Microsoft and Procter & Gamble
JNJ: 105.56 (+0.77), AMZN: 294.12 (-1.47), GILD: 110.72 (-2.73), MRK: 56.20 (+0.35), PFE: 29.49 (+0.40), ABBV: 59.98 (-0.95), PG: 86.54 (+0.07), MSFT: 46.62 (+0.13)
Shire (SHPG) Gains on Q3 Earnings Beat, Ups Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 9:03AM CDT
Shire reported third-quarter 2014 earnings (excluding special items and amortization) of $2.93 per American Depositary Share (ADS), up from $1.83 per ADS in the year-ago quarter and beating the Zacks Consensus Estimate of $2.47.
AGN: 186.77 (+4.17), VRX: 129.76 (-1.31), SHPG: 196.45 (-1.35), ABBV: 59.98 (-0.95)
How Gilead Sciences Inc. Isn't Gouging Hepatitis C Patients, in 1 Simple Infographic
Brian Orelli, The Motley Fool - Motley Fool - Sun Oct 26, 10:15AM CDT
Gilead Sciences recently got its hepatitis C drug Harvoni approved by the Food and Drug Administration and announced that it would cost $94,500, substantially more than the $84,000 that wholesalers pay for Sovaldi, one of the two components of...
ESRX: 74.03 (-0.38), GILD: 110.72 (-2.73), MRK: 56.20 (+0.35), AZN: 71.53 (+0.10), ABBV: 59.98 (-0.95), BMY: 54.16 (-0.04)
Shire EPS Growth Accelerates, Stock Continues Rebound
at Investor's Business Daily - Fri Oct 24, 10:12AM CDT
Irish drugmaker Shire (SHPG) beat Wall Street's Q3 estimates and raised its guidance Friday, sending its beleaguered stock up more than 5% on the stock market today to 194.84. Earnings excluding one-time items rose 60% over the year-earlier quarter...
SHPG: 196.45 (-1.35), ABBV: 59.98 (-0.95)
Revlimid: Celgene Corporation's Gift That Keeps on Giving
Brian Orelli, The Motley Fool - Motley Fool - Thu Oct 23, 12:06PM CDT
Celgene posted a solid third quarter earnings report with product sales up 19% -- with most of that coming from increases in volume -- and adjusted earnings per share up 24%. But when you dive down to the individual drug level, it was a tale of...
ABBV: 59.98 (-0.95), CELG: 105.14 (-0.56)
AbbVie Named a Top Employer in Science Magazine's Annual Survey for Second Consecutive Year
PR Newswire - Thu Oct 23, 7:00AM CDT
AbbVie (NYSE: ABBV) today announced that Science/Science Careers has included AbbVie in its annual Top Employers Survey, as surveyed by more than 5,000 respondents in the biotechnology, pharmaceutical and biopharmaceutical industries.
ABBV: 59.98 (-0.95)
'Fast Money' Recap: Look to Exxon Mobil as Oil Continues Lower
at The Street - Thu Oct 23, 4:00AM CDT
The trading panel discussed the S&P 500 and high-quality stocks worth the investment.
HYG: 92.49 (-0.07), HD: 96.42 (-0.17), VMW: 83.81 (-1.59), BRCM: 40.33 (-0.09), DDD: 37.10 (-1.82), XOM: 94.59 (-0.51), AMGN: 158.88 (+1.69), RGLS: 18.08 (+0.47), HAIN: 105.91 (+1.17), YHOO: 45.43 (-0.44), JNJ: 105.56 (+0.77), MRK: 56.20 (+0.35), ANGI: 6.57 (-0.17), DIA: 169.40 (-0.26), BDBD: 8.60 (+0.02), ABBV: 59.98 (-0.95), IWM: 113.90 (-0.27), YELP: 56.68 (-2.43), IRBT: 34.71 (+0.24)
Gilead's Hep C Dream Drug Faces Demanding Investors
at Investor's Business Daily - Wed Oct 22, 3:44PM CDT
For decades, Charlotte Stewart was carrying around a virus that was like the houseguest that refused to leave: hepatitis C. Stewart was first diagnosed with HCV in 1998, but she believes she contracted it as much as 20 years earlier, when she...
GILD: 110.72 (-2.73), MRK: 56.20 (+0.35), ABBV: 59.98 (-0.95)
Will AbbVie (ABBV) Disappoint in this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 2:28PM CDT
AbbVie (ABBV) is scheduled to report its third-quarter 2014 results before the opening bell on Oct 31.
INCY: 57.87 (-0.32), TEVA: 54.49 (-0.31), AMAG: 33.26 (-0.75), ABBV: 59.98 (-0.95)
3 Health Care Picks To Beat Earnings - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 11:09AM CDT
These stocks are well positioned in today's market environment.
ENDP: 65.65 (-0.93), VRX: 129.76 (-1.31), ACT: 238.78 (-0.25), AMGN: 158.88 (+1.69), TKMR: 16.87 (-1.46), GSK: 45.08 (-0.02), AGN: 186.77 (+4.17), JNJ: 105.56 (+0.77), SHPG: 196.45 (-1.35), MRK: 56.20 (+0.35), INFI: 13.58 (-0.08), ABBV: 59.98 (-0.95), KPTI: 39.81 (+1.78)
Gilead Beats on Q3 Earnings, Sovaldi Sales Fall Sequentially - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 8:00AM CDT
Gilead Sciences, Inc. reported third-quarter earnings (including stock-based compensation expenses) of $1.79 per share.
AGN: 186.77 (+4.17), GILD: 110.72 (-2.73), MRK: 56.20 (+0.35), ABBV: 59.98 (-0.95)
If You Purchased Shire plc American Depository Receipts ("ADRs"
During The Period Of June 20, 2014 And October 14, 2014 And Lost Money, Gardy & Notis, LLP Encourages You To Contact The Law Firm PR Newswire - Wed Oct 29, 7:38AM CDT
Gardy & Notis, LLP, a national law firm advocating for shareholder rights, is investigating AbbVie Inc. (NYSE: ABBV) and its officers and directors in connection with statements distributed by, or on behalf of, AbbVie to purchasers of Shire plc ADRs (NASDAQ: SHPG) and the general investing public regarding AbbVie's rationale for pursuing a business combination with Shire.
SHPG: 196.45 (-1.35), ABBV: 59.98 (-0.95)
Compliance Notice, Dividend Announcements, New Share Repurchase Program, and Financial Results - Research Reports on Gilead, Pfizer, AbbVie, Edwards and Lilly
PR Newswire - Wed Oct 29, 7:35AM CDT
Today, Analysts Review released its research reports regarding Gilead Sciences, Inc. (NASDAQ: GILD), Pfizer Inc. (NYSE: PFE), AbbVie Inc. (NYSE: ABBV), Edwards Lifesciences Corp. (NYSE: EW) and Eli Lilly and Co. (NYSE: LLY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7520-100free.
GILD: 110.72 (-2.73), PFE: 29.49 (+0.40), EW: 120.00 (+1.72), LLY: 65.49 (+0.66), ABBV: 59.98 (-0.95)
Pfizer Q3 Earnings Top Estimates Despite Generic Pressure - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 3:10PM CDT
Pfizer's (PFE) third quarter earnings and revenues were better-than-expected despite the presence of generic pressure.
AGN: 186.77 (+4.17), BIIB: 315.06 (-2.97), PFE: 29.49 (+0.40), ABBV: 59.98 (-0.95)
Amgen Refuses To Split, But Plans Hearten Investors
at Investor's Business Daily - Tue Oct 28, 1:18PM CDT
Big-cap biotech Amgen (AMGN) offered 2015 guidance, set 2018 targets and resisted pressure to split at a business-review meeting Tuesday. On the heels of Monday's Q3 earnings beat, Amgen's action helped drive the stock up more than 5% in afternoon...
AMGN: 158.88 (+1.69), ABBV: 59.98 (-0.95)
Receptos Soars After Lead Drug Racks Up Another Win
at Investor's Business Daily - Tue Oct 28, 10:46AM CDT
Receptos (RCPT) stock jumped more than 47% to a new high above 99 in morning trading on the stock market today, and the company got multiple price-target increases after its bowel-disease drug succeeded in a midstage trial. Receptos announced late...
JNJ: 105.56 (+0.77), RCPT: 98.30 (+2.54), ABBV: 59.98 (-0.95)
3 Generics Stocks to Buy Now - Analyst Blog
Swarup Gupta - Zacks Investment Research - Tue Oct 28, 9:28AM CDT
Data from IMS health show that 29% of expenditure on prescription drugs in the U.S. can be attributed to generics.
MNK: 93.01 (-0.73), ABT: 42.74 (+0.24), ACT: 238.78 (-0.25), MYL: 50.85 (-0.86), ABBV: 59.98 (-0.95)
Was AbbVie Inc. Wrong to Abandon Its Deal With Shire plc?
Todd Campbell, The Motley Fool - Motley Fool - Tue Oct 28, 8:45AM CDT
Source: Shire Tax inversions are dead. The Treasury Department made sure of that in September, when it released a shopping list of changes to rein in proposed transactions like the one previously planned between AbbVie and Shire plc . ...
SHPG: 196.45 (-1.35), ABBV: 59.98 (-0.95)
Global Schizoaffective Disorder Clinical Trials Report H2, 2014
M2 - Tue Oct 28, 5:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3w59x2/schizoaffective) has announced the addition of the "Schizoaffective Disorder Global Clinical Trials Review, H2, 2014" report to their offering. Schizoaffective Disorder Global Clinical Trials Review, H2, 2014" provides data on the Schizoaffective Disorder clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Schizoaffective Disorder. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Schizoaffective Disorder. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies - Johnson & Johnson - Pfizer Inc. - Eli Lilly and Company - AstraZeneca PLC - Bristol-Myers Squibb Company - Sumitomo Dainippon Pharma Co., Ltd. - Otsuka Holdings Co., Ltd. - AbbVie Inc. - North Shore-Long Island Jewish Health System, Inc. - Merck & Co., Inc. Top Institutes / Government - U.S. Department of Veterans Affairs - University of Maryland - University of Pittsburgh - Yale University - Centre for Addiction and Mental Health - National Institute of Mental Health - Vanderbilt University - Dartmouth-Hitchcock Medical Center - Massachusetts General Hospital - North Suffolk Mental Health Association For more information visit http://www.researchandmarkets.com/research/3w...oaffective
JNJ: 105.56 (+0.77), PFE: 29.49 (+0.40), MRK: 56.20 (+0.35), AZN: 71.53 (+0.10), LLY: 65.49 (+0.66), ABBV: 59.98 (-0.95), BMY: 54.16 (-0.04)
Video: Allergan Lifts Views; Valeant Suggests Higher Bid
at Investor's Business Daily - Mon Oct 27, 11:17AM CDT
Specialty drugmaker Allergan (AGN) reported solid Q3 results and raised its guidance Monday, as hostile suitor Valeant Pharmaceuticals International (VRX) said that it might raise its bid for the company again. Allergan's Q3 earnings rose 45% over...
AGN: 186.77 (+4.17), ACT: 238.78 (-0.25), VRX: 129.76 (-1.31), SHPG: 196.45 (-1.35), ABBV: 59.98 (-0.95)
Stock Market News for October 27, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 9:10AM CDT
Benchmarks posted solid gains on Friday, banking on upbeat quarterly results from Microsoft and Procter & Gamble
JNJ: 105.56 (+0.77), AMZN: 294.12 (-1.47), GILD: 110.72 (-2.73), MRK: 56.20 (+0.35), PFE: 29.49 (+0.40), ABBV: 59.98 (-0.95), PG: 86.54 (+0.07), MSFT: 46.62 (+0.13)
Shire (SHPG) Gains on Q3 Earnings Beat, Ups Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 9:03AM CDT
Shire reported third-quarter 2014 earnings (excluding special items and amortization) of $2.93 per American Depositary Share (ADS), up from $1.83 per ADS in the year-ago quarter and beating the Zacks Consensus Estimate of $2.47.
AGN: 186.77 (+4.17), VRX: 129.76 (-1.31), SHPG: 196.45 (-1.35), ABBV: 59.98 (-0.95)
How Gilead Sciences Inc. Isn't Gouging Hepatitis C Patients, in 1 Simple Infographic
Brian Orelli, The Motley Fool - Motley Fool - Sun Oct 26, 10:15AM CDT
Gilead Sciences recently got its hepatitis C drug Harvoni approved by the Food and Drug Administration and announced that it would cost $94,500, substantially more than the $84,000 that wholesalers pay for Sovaldi, one of the two components of...
ESRX: 74.03 (-0.38), GILD: 110.72 (-2.73), MRK: 56.20 (+0.35), AZN: 71.53 (+0.10), ABBV: 59.98 (-0.95), BMY: 54.16 (-0.04)
Shire EPS Growth Accelerates, Stock Continues Rebound
at Investor's Business Daily - Fri Oct 24, 10:12AM CDT
Irish drugmaker Shire (SHPG) beat Wall Street's Q3 estimates and raised its guidance Friday, sending its beleaguered stock up more than 5% on the stock market today to 194.84. Earnings excluding one-time items rose 60% over the year-earlier quarter...
SHPG: 196.45 (-1.35), ABBV: 59.98 (-0.95)
Revlimid: Celgene Corporation's Gift That Keeps on Giving
Brian Orelli, The Motley Fool - Motley Fool - Thu Oct 23, 12:06PM CDT
Celgene posted a solid third quarter earnings report with product sales up 19% -- with most of that coming from increases in volume -- and adjusted earnings per share up 24%. But when you dive down to the individual drug level, it was a tale of...
ABBV: 59.98 (-0.95), CELG: 105.14 (-0.56)
AbbVie Named a Top Employer in Science Magazine's Annual Survey for Second Consecutive Year
PR Newswire - Thu Oct 23, 7:00AM CDT
AbbVie (NYSE: ABBV) today announced that Science/Science Careers has included AbbVie in its annual Top Employers Survey, as surveyed by more than 5,000 respondents in the biotechnology, pharmaceutical and biopharmaceutical industries.
ABBV: 59.98 (-0.95)
'Fast Money' Recap: Look to Exxon Mobil as Oil Continues Lower
at The Street - Thu Oct 23, 4:00AM CDT
The trading panel discussed the S&P 500 and high-quality stocks worth the investment.
HYG: 92.49 (-0.07), HD: 96.42 (-0.17), VMW: 83.81 (-1.59), BRCM: 40.33 (-0.09), DDD: 37.10 (-1.82), XOM: 94.59 (-0.51), AMGN: 158.88 (+1.69), RGLS: 18.08 (+0.47), HAIN: 105.91 (+1.17), YHOO: 45.43 (-0.44), JNJ: 105.56 (+0.77), MRK: 56.20 (+0.35), ANGI: 6.57 (-0.17), DIA: 169.40 (-0.26), BDBD: 8.60 (+0.02), ABBV: 59.98 (-0.95), IWM: 113.90 (-0.27), YELP: 56.68 (-2.43), IRBT: 34.71 (+0.24)
Gilead's Hep C Dream Drug Faces Demanding Investors
at Investor's Business Daily - Wed Oct 22, 3:44PM CDT
For decades, Charlotte Stewart was carrying around a virus that was like the houseguest that refused to leave: hepatitis C. Stewart was first diagnosed with HCV in 1998, but she believes she contracted it as much as 20 years earlier, when she...
GILD: 110.72 (-2.73), MRK: 56.20 (+0.35), ABBV: 59.98 (-0.95)
